Mapi - Pharma (Mapi - Pharma) Change In Inventory : $0.00 Mil (TTM As of Jun. 2015)

View and export this data going back to . Start your Free Trial

What is Mapi - Pharma Change In Inventory?

Mapi - Pharma's change in inventory for the quarter that ended in Jun. 2015 was $0.00 Mil. It means Mapi - Pharma's inventory stayed the same from Dec. 2014 to Jun. 2015 .

Mapi - Pharma's change in inventory for the fiscal year that ended in Dec. 2014 was $0.00 Mil. It means Mapi - Pharma's inventory stayed the same from Dec. 2013 to Dec. 2014 .

Mapi - Pharma's Total Inventories for the quarter that ended in Jun. 2015 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Mapi - Pharma Change In Inventory Historical Data

The historical data trend for Mapi - Pharma's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mapi - Pharma Change In Inventory Chart

Mapi - Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Change In Inventory

Mapi - Pharma Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15
Change In Inventory	-	-	-	-	-

Mapi - Pharma Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2015 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

Mapi - Pharma (NAS:MAPI) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Mapi - Pharma's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 2
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Mapi - Pharma's Inventory Turnover for the quarter that ended in Jun. 2015 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Mapi - Pharma's Inventory to Revenue for the quarter that ended in Jun. 2015 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Mapi - Pharma Change In Inventory Related Terms

Thank you for viewing the detailed overview of Mapi - Pharma's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Mapi - Pharma (Mapi - Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.mapi-pharma.com

Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.